Romosozumab - CISMeF

Preferred Label : Romosozumab;

NCIt synonyms : Romosozumab-aqqg;

NCIt definition : A recombinant humanized immunoglobulin G2 (IgG2) monoclonal antibody directed against sclerostin, with anti-osteoporotic activity. Upon administration, romosozumab targets, binds to and inhibits the activity of sclerostin, a regulatory factor in bone metabolism. This stimulates osteoblastic activity, increases bone formation and, to a lesser extent, decreases bone resorption This may increase trabecular and cortical bone mass and improve bone structure and strength. Altogether, this may decrease the risk of fractures. Sclerostin, a negative regulator of bone formation secreted by osteocytes, inhibits Wnt signaling and suppresses osteoblast development and function.;

UNII : 3VHF2ZD92J;

CAS number : 909395-70-6;

Drug name : Evenity;

Details

Origin ID

C152246;

UMLS CUI

C3661283;

Automatic exact mappings (from CISMeF team)
- romosozumab [ATC Code]
Currated CISMeF NLP mapping
- Romosozumab [ICD-11 Extension code]
- Romosozumab [SMS substance]
- Romosozumab (substance) [SNOMED CT concept]
- romosozumab [MeSH Supplementary Concept]
- romosozumab [MeSH concept]
Semantic type(s)
- Amino Acid, Peptide, or Protein [UMLS semantic type]
- Immunologic Factor [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- Product containing romosozumab (medicinal product) [SNOMED CT concept]
- Romosozumab (substance) [SNOMED CT concept]
- romosozumab [ATC Code]
- romosozumab [MeSH concept]
- romosozumab [MeSH Supplementary Concept]
chemical_or_drug_has_mechanism_of_action
- Antigen Binding [NCIt concept]
concept_is_in_subset
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients